Prevention of preterm delivery with 17-hydroxyprogesterone caproate: pharmacologic considerations
about
Prenatal administration of progestogens for preventing preterm birth in women with a multiple pregnancyPrenatal administration of progestogens for preventing spontaneous preterm birth in women with a multiple pregnancy.The value of oral micronized progesterone in the prevention of recurrent spontaneous preterm birth: a randomized controlled trial.The association among cytochrome P450 3A, progesterone receptor polymorphisms, plasma 17-alpha hydroxyprogesterone caproate concentrations, and spontaneous preterm birth.The impact of low-dose aspirin on preterm birth: secondary analysis of a randomized controlled trial.
P2860
Prevention of preterm delivery with 17-hydroxyprogesterone caproate: pharmacologic considerations
description
2014 nî lūn-bûn
@nan
2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Prevention of preterm delivery ...... : pharmacologic considerations
@ast
Prevention of preterm delivery ...... : pharmacologic considerations
@en
Prevention of preterm delivery ...... : pharmacologic considerations
@nl
type
label
Prevention of preterm delivery ...... : pharmacologic considerations
@ast
Prevention of preterm delivery ...... : pharmacologic considerations
@en
Prevention of preterm delivery ...... : pharmacologic considerations
@nl
prefLabel
Prevention of preterm delivery ...... : pharmacologic considerations
@ast
Prevention of preterm delivery ...... : pharmacologic considerations
@en
Prevention of preterm delivery ...... : pharmacologic considerations
@nl
P2093
P2860
P1476
Prevention of preterm delivery ...... : pharmacologic considerations
@en
P2093
Maisa Feghali
Raman Venkataramanan
Steve Caritis
P2860
P304
P356
10.1053/J.SEMPERI.2014.08.013
P407
P577
2014-12-01T00:00:00Z